Literature DB >> 31474574

Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1.

Jian Zhang1, Abdullah M Ali2, Yen K Lieu3, Zhaoqi Liu4, Jianchao Gao1, Raul Rabadan4, Azra Raza5, Siddhartha Mukherjee6, James L Manley7.   

Abstract

SF3B1, which encodes an essential spliceosomal protein, is frequently mutated in myelodysplastic syndromes (MDS) and many cancers. However, the defect of mutant SF3B1 is unknown. Here, we analyzed RNA sequencing data from MDS patients and confirmed that SF3B1 mutants use aberrant 3' splice sites. To elucidate the underlying mechanism, we purified complexes containing either wild-type or the hotspot K700E mutant SF3B1 and found that levels of a poorly studied spliceosomal protein, SUGP1, were reduced in mutant spliceosomes. Strikingly, SUGP1 knockdown completely recapitulated the splicing errors, whereas SUGP1 overexpression drove the protein, which our data suggest plays an important role in branchsite recognition, into the mutant spliceosome and partially rescued splicing. Other hotspot SF3B1 mutants showed similar altered splicing and diminished interaction with SUGP1. Our study demonstrates that SUGP1 loss is a common defect of spliceosomes with disease-causing SF3B1 mutations and, because this defect can be rescued, suggests possibilities for therapeutic intervention.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  SF1; SRSF2; U2 snRNP; U2AF1; U2AF2; branch point; leukemia; myelodysplastic syndromes; p14; spliceosome

Mesh:

Substances:

Year:  2019        PMID: 31474574      PMCID: PMC7065273          DOI: 10.1016/j.molcel.2019.07.017

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  71 in total

1.  Interaction between the Spliceosomal Pre-mRNA Branch Site and U2 snRNP Protein p14.

Authors:  William Perea; Kersten T Schroeder; Amy N Bryant; Nancy L Greenbaum
Journal:  Biochemistry       Date:  2016-01-25       Impact factor: 3.162

2.  Multiple U2AF65 binding sites within SF3b155: thermodynamic and spectroscopic characterization of protein-protein interactions among pre-mRNA splicing factors.

Authors:  Karen R Thickman; Matthew C Swenson; Joseph M Kabogo; Zygmunt Gryczynski; Clara L Kielkopf
Journal:  J Mol Biol       Date:  2005-12-07       Impact factor: 5.469

3.  Nonconsensus branch-site sequences in the in vitro splicing of transcripts of mutant rabbit beta-globin genes.

Authors:  R A Padgett; M M Konarska; M Aebi; H Hornig; C Weissmann; P A Sharp
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

4.  SRSF2 Is Essential for Hematopoiesis, and Its Myelodysplastic Syndrome-Related Mutations Dysregulate Alternative Pre-mRNA Splicing.

Authors:  Yukiko Komeno; Yi-Jou Huang; Jinsong Qiu; Leo Lin; YiJun Xu; Yu Zhou; Liang Chen; Dora D Monterroza; Hairi Li; Russell C DeKelver; Ming Yan; Xiang-Dong Fu; Dong-Er Zhang
Journal:  Mol Cell Biol       Date:  2015-06-29       Impact factor: 4.272

5.  U2AF65 recruits a novel human DEAD box protein required for the U2 snRNP-branchpoint interaction.

Authors:  J Fleckner; M Zhang; J Valcárcel; M R Green
Journal:  Genes Dev       Date:  1997-07-15       Impact factor: 11.361

6.  SF4 and SFRS14, two related putative splicing factors on human chromosome 19p13.11.

Authors:  Natalie D Sampson; Jane E Hewitt
Journal:  Gene       Date:  2003-02-13       Impact factor: 3.688

7.  Small-molecule stabilization of the p53 - 14-3-3 protein-protein interaction.

Authors:  Richard G Doveston; Ave Kuusk; Sebastian A Andrei; Seppe Leysen; Qing Cao; Maria P Castaldi; Adam Hendricks; Luc Brunsveld; Hongming Chen; Helen Boyd; Christian Ottmann
Journal:  FEBS Lett       Date:  2017-08-06       Impact factor: 4.124

8.  H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.

Authors:  Michael Seiler; Akihide Yoshimi; Rachel Darman; Betty Chan; Gregg Keaney; Michael Thomas; Anant A Agrawal; Benjamin Caleb; Alfredo Csibi; Eckley Sean; Peter Fekkes; Craig Karr; Virginia Klimek; George Lai; Linda Lee; Pavan Kumar; Stanley Chun-Wei Lee; Xiang Liu; Crystal Mackenzie; Carol Meeske; Yoshiharu Mizui; Eric Padron; Eunice Park; Ermira Pazolli; Shouyong Peng; Sudeep Prajapati; Justin Taylor; Teng Teng; John Wang; Markus Warmuth; Huilan Yao; Lihua Yu; Ping Zhu; Omar Abdel-Wahab; Peter G Smith; Silvia Buonamici
Journal:  Nat Med       Date:  2018-02-19       Impact factor: 53.440

9.  Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage.

Authors:  Samar Alsafadi; Alexandre Houy; Aude Battistella; Tatiana Popova; Michel Wassef; Emilie Henry; Franck Tirode; Angelos Constantinou; Sophie Piperno-Neumann; Sergio Roman-Roman; Martin Dutertre; Marc-Henri Stern
Journal:  Nat Commun       Date:  2016-02-04       Impact factor: 17.694

10.  Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3' splice sites within RNA secondary structures.

Authors:  A K Kesarwani; O Ramirez; A K Gupta; X Yang; T Murthy; A C Minella; M M Pillai
Journal:  Oncogene       Date:  2016-08-15       Impact factor: 9.867

View more
  28 in total

Review 1.  The pancreatic cancer genome revisited.

Authors:  Akimasa Hayashi; Jungeui Hong; Christine A Iacobuzio-Donahue
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-06-04       Impact factor: 46.802

Review 2.  Structural and functional modularity of the U2 snRNP in pre-mRNA splicing.

Authors:  Clarisse van der Feltz; Aaron A Hoskins
Journal:  Crit Rev Biochem Mol Biol       Date:  2019-11-20       Impact factor: 8.250

Review 3.  Targeting transcription cycles in cancer.

Authors:  Stephin J Vervoort; Jennifer R Devlin; Nicholas Kwiatkowski; Mingxing Teng; Nathanael S Gray; Ricky W Johnstone
Journal:  Nat Rev Cancer       Date:  2021-10-21       Impact factor: 60.716

Review 4.  RNA-binding proteins of COSMIC importance in cancer.

Authors:  Peter S Choi; Andrei Thomas-Tikhonenko
Journal:  J Clin Invest       Date:  2021-09-15       Impact factor: 19.456

Review 5.  Dysregulation and therapeutic targeting of RNA splicing in cancer.

Authors:  Robert F Stanley; Omar Abdel-Wahab
Journal:  Nat Cancer       Date:  2022-05-27

Review 6.  Roles and mechanisms of alternative splicing in cancer - implications for care.

Authors:  Sophie C Bonnal; Irene López-Oreja; Juan Valcárcel
Journal:  Nat Rev Clin Oncol       Date:  2020-04-17       Impact factor: 66.675

7.  Pan-cancer analysis identifies mutations in SUGP1 that recapitulate mutant SF3B1 splicing dysregulation.

Authors:  Zhaoqi Liu; Jian Zhang; Yiwei Sun; Tomin E Perea-Chamblee; James L Manley; Raul Rabadan
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-24       Impact factor: 11.205

8.  Molecular architecture of the human 17S U2 snRNP.

Authors:  Zhenwei Zhang; Cindy L Will; Karl Bertram; Olexandr Dybkov; Klaus Hartmuth; Dmitry E Agafonov; Romina Hofele; Henning Urlaub; Berthold Kastner; Reinhard Lührmann; Holger Stark
Journal:  Nature       Date:  2020-06-03       Impact factor: 49.962

Review 9.  Computing the Role of Alternative Splicing in Cancer.

Authors:  Zhaoqi Liu; Raul Rabadan
Journal:  Trends Cancer       Date:  2021-01-23

10.  Functional and conformational impact of cancer-associated SF3B1 mutations depends on the position and the charge of amino acid substitution.

Authors:  Christine Canbezdi; Malcy Tarin; Alexandre Houy; Dorine Bellanger; Tatiana Popova; Marc-Henri Stern; Sergio Roman-Roman; Samar Alsafadi
Journal:  Comput Struct Biotechnol J       Date:  2021-02-27       Impact factor: 7.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.